Mucormycosis: its contemporary face and management strategies

被引：107
作者：
Sun, Hsin-Yun [1 ,2 ,3 ]
Singh, Nina [1 ,4 ]
机构：
[1] VA Pittsburgh Healthcare Syst, Infect Dis Sect, Pittsburgh, PA USA
[2] Natl Taiwan Univ Hosp, Dept Internal Med, Taipei 100, Taiwan
[3] Natl Taiwan Univ, Coll Med, Taipei 10764, Taiwan
[4] Univ Pittsburgh, Dept Med, Div Infect Dis, Pittsburgh, PA USA
来源：
LANCET INFECTIOUS DISEASES | 2011年 / 11卷 / 04期
关键词：
LIPOSOMAL AMPHOTERICIN-B; ORGAN TRANSPLANT RECIPIENTS; INVASIVE FUNGAL-INFECTIONS; CALCINEURIN-INHIBITOR AGENTS; STEM-CELL TRANSPLANTATION; COLONY-STIMULATING FACTOR; LIPID COMPLEX; IN-VITRO; HYPERBARIC-OXYGEN; BREAKTHROUGH ZYGOMYCOSIS;
D O I：
10.1016/S1473-3099(10)70316-9
中图分类号：
R51 [传染病];
学科分类号：
100401 ;
摘要：
Several countries have seen rising frequencies of mucormycosis among patients with haematological disorders, malignancies, or diabetes mellitus, and among transplant recipients. Growing numbers of immunocompromised hosts, widespread use of antifungal agents inactive against mucormycosis, or other unidentified factors, could be contributing to this situation. The predominant clinical manifestations of mucormycosis vary from host to host. Additionally, risk factors specific to different subgroups have been identified, such as leukaemia, allogeneic haemopoietic stem-cell transplant, voriconazole prophylaxis, diabetes, and malnutrition. We summarise the current state of knowledge of characteristics and risk factors and discuss topical developments in therapeutic methods and strategies in the management of mucormycosis.
引用
收藏
页码：301 / 311
页数：11
相关论文
共 137 条
[1]   Interferon-γ and colony-stimulating factors as adjuvant therapy for refractory fungal infections in children [J].
Abzug, MJ ;
Walsh, TJ .
PEDIATRIC INFECTIOUS DISEASE JOURNAL, 2004, 23 (08) :769-773
[2]   In vitro activity of antifungals against Zygomycetes [J].
Alastruey-Izquierdo, A. ;
Castelli, M. V. ;
Cuesta, I. ;
Zaragoza, O. ;
Monzon, A. ;
Mellado, E. ;
Rodriguez-Tudela, J. L. .
CLINICAL MICROBIOLOGY AND INFECTION, 2009, 15 :71-76
[3]  
ALBERT MM, 1995, J MYCOL MED, V5, P1
[4]   Zygomycosis in solid organ transplant recipients in a tertiary transplant center and review of the literature [J].
Almyroudis, N. G. ;
Sutton, D. A. ;
Linden, P. ;
Rinaldi, M. G. ;
Fung, J. ;
Kusne, S. .
AMERICAN JOURNAL OF TRANSPLANTATION, 2006, 6 (10) :2365-2374
[5]   Outbreaks of zygomycosis in hospitals [J].
Antoniadou, A. .
CLINICAL MICROBIOLOGY AND INFECTION, 2009, 15 :55-59
[6]   Immunopharmacology of modern antifungals [J].
Ben-Ami, R. ;
Lewis, R. E. ;
Kontoyiannis, D. P. .
CLINICAL INFECTIOUS DISEASES, 2008, 47 (02) :226-235
[7]   Antifungal Activity of Colistin against Mucorales Species In Vitro and in a Murine Model of Rhizopus oryzae Pulmonary Infection [J].
Ben-Ami, Ronen ;
Lewis, Russell E. ;
Tarrand, Jeffrey ;
Leventakos, Konstantinos ;
Kontoyiannis, Dimitrios P. .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2010, 54 (01) :484-490
[8]  
BENNETT JE, 2009, PRINCIPLES PRACTICE
[9]  
Best LA, 2009, 47 ANN M INF DIS SOC
[10]   Increasing Incidence of Zygomycosis (Mucormycosis), France, 1997-2006 [J].
Bitar, Dounia ;
Van Cauteren, Dieter ;
Lanternier, Fanny ;
Dannaoui, Eric ;
Che, Didier ;
Dromer, Francoise ;
Desenclos, Jean-Claude ;
Lortholary, Olivier .
EMERGING INFECTIOUS DISEASES, 2009, 15 (09) :1395-1401
12345678910